Business Wire

Hytera Mission-critical Push-to-talk Solution Wins Flagship Industry Award

Share

Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, received the award of “Best use of critical communications in utilities” with its entry “LECO Electricity MCPTT” at the International Critical Communications Awards (ICCAs) 2023 ceremony held in Helsinki, Finland on May 23. The ICCAs, presented by the Critical Communications Association (TCCA), is a highly-anticipated program recognizing the success of products, organizations, and individuals that have pushed boundaries and capabilities within the field of critical communications. Earlier in April, Hytera’s seven entries were shortlisted by ICCAs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005622/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tony Gray, former CEO of TCCA, presenting the ICCA award to Hytera representative (on the right) (Photo: Business Wire)

This Mission-critical Push-to-talk (MCPTT) deployment highlights a clear path for the migration of the private communications network in the utility sector. Working with local partner Dialog Enterprise, Hytera has deployed a customized MCPTT system for LECO, Lanka Electricity Company (Private) Limited. As the rapid-response arm of the Ceylon Electricity Board, LECO provides electrical services to underserved areas and now works with a state-of-the-art radio communications system based on MCPTT over 4G-LTE technology to cover service grids in Galle, Moratuwa, Kalutara, Negombo, Kelaniya, Kotte, and Nugegoda. In the extreme scenario where cellular network coverage is not available, Hytera’s dual-mode rugged radios support device-to-device (D2D) communication empowered by Digital Mobile Radio (DMR) technology. While it proves the versatility of MCPTT to serve utility companies, the project also demonstrates how product innovations, such as dual-mode radios, can win the users’ buy-ins in technology adoption.

“This MCPTT solution operates at a higher priority than Internet services, and also having a device-to-device communication mode are huge pluses for LECO,” said Athula P. De Silva, Chairman of LECO. “Because when connectivity is interrupted due to unforeseeable circumstances–like a sudden violent storm, for instance–we are the professionals whose job it is to bring the network back up. With this, our dispatchers and field engineers are in constant touch since we are in complete control of our own internal communication channel. So, in the event of an outage, power can be restored much faster. If we had chosen the generic mobile voice service or Push-to-talk over Cellular (PoC) instead, our rapid response team’s communications would have been vulnerable to the same disruptive factors and service interruptions as the general public–and that was totally unacceptable. We are the first line of defense against power outages. MCPTT solution is a perfect fit for our requirements.”

Hytera HyTalk MC Mission Critical Services (MCS) system is a multimedia mission-critical communication solution designed for sectors such as public safety, utilities, and transportation. It is fully compliant with the 3GPP MC standards including MCPTT, MCData, and MCVideo. It delivers reliable voice and video communication, high-speed data transfer, and multimedia dispatch services for daily operations. It helps enhance connectivity for better collaboration and improved situational awareness.

Priority Quality of Service (QoS) of HyTalk MC is guaranteed on the servers of the MCPTT platform provider and on the mobile operator's network. This end-to-end QoS ensures that critical communications users are given the highest priority available over any other commercial users. HyTalk MC also enables Professional Mobile Radio (PMR) to LTE interoperability, so that it allows connections among different task forces.

“The award is a great recognition to all the stakeholders of this project, including LECO and Dialog. This case epitomizes how technological advancements are introduced and adopted to empower professionals from the utility sector,” said Ming Kam Wong, deputy GM of Hytera overseas business, who was present at the ICCAs ceremony. “Hytera is humbled to see itself becoming a frequent participant and winner of ICCAs. Thank you to the panel and congratulations to all the winners of ICCAs 2023.”

About Hytera

Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/home.html.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

lele.yao@hytera.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye